Risk factors for mortality in Stenotrophomonas maltophilia bacteremia – a meta-analysis

References

• Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998;11(1):57–80. doi: 10.1128/CMR.11.1.57.
   PubMed Web of Science ®Google Scholar
• Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25(1):2–41. doi: 10.1128/CMR.00019-11.
   PubMed Web of Science ®Google Scholar
• Adegoke AA, Stenström TA, Okoh AI. Stenotrophomonas maltophilia as an emerging ubiquitous pathogen: looking beyond contemporary antibiotic therapy. Front Microbiol. 2017;8:2276. doi: 10.3389/fmicb.2017.02276.
   PubMed Web of Science ®Google Scholar
• Carmody LA, Spilker T, LiPuma JJ. Reassessment of Stenotrophomonas maltophilia phenotype. J Clin Microbiol. 2011;49(3):1101–1103. doi: 10.1128/JCM.02204-10.
   PubMed Web of Science ®Google Scholar
• Cervia JS, Ortolano GA, Canonica FP. Hospital tap water as a source of Stenotrophomonas maltophilia infection. Clin Infect Dis. 2008;46(9):1485–1487. doi: 10.1086/587180.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kastoris AC, Vouloumanou EK, et al. Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol. 2009;4(9):1103–1109. doi: 10.2217/fmb.09.84.
   PubMed Web of Science ®Google Scholar
• Micozzi A, Venditti M, Monaco M, et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis. 2000;31(3):705–711. doi: 10.1086/314043.
   PubMed Web of Science ®Google Scholar
• Labarca JA, Leber AL, Kern VL, et al. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis. 2000;30(1):195–197. doi: 10.1086/313591.
   PubMed Web of Science ®Google Scholar
• Insuwanno W, Kiratisin P, Jitmuang A. Stenotrophomonas maltophilia infections: clinical characteristics and factors associated with mortality of hospitalized patients. Infect Drug Resist. 2020;13:1559–1566. doi: 10.2147/IDR.S253949.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob Agents Chemother. 2000;44(2):287–293. doi: 10.1128/AAC.44.2.287-293.2000.
   PubMed Web of Science ®Google Scholar
• Alonso A, Martínez JL. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 1997;44(11):3079–3086. doi: 10.1128/AAC.41.5.1140.
   Google Scholar
• Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis. 2007;26(4):229–237. doi: 10.1007/s10096-007-0279-3.
   PubMed Web of Science ®Google Scholar
• Chung HS, Hong SG, Kim YR, et al. Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates. J Korean Med Sci. 2013;28(1):62–66. doi: 10.3346/jkms.2013.28.1.62.
   PubMed Web of Science ®Google Scholar
• Hu LF, Xu XH, Li HR, et al. Surveillance of antimicrobial susceptibility patterns among Stenotrophomonas maltophilia isolated in China during the 10-year period of 2005–2014. J Chemother. 2018;30(1):25–30. doi: 10.1080/1120009X.2017.1378834.
   PubMed Web of Science ®Google Scholar
• Lawson DH, Paice BJ. Adverse reactions to trimethoprim–sulfamethoxazole. Rev Infect Dis. 1982;4(2):429–433. doi: 10.1093/clinids/4.2.429.
   PubMedGoogle Scholar
• Ho JM, Juurlink DN. Considerations when prescribing trimethoprim–sulfamethoxazole. CMAJ. 2011;183(16):1851–1858. doi: 10.1503/cmaj.111152.
   PubMed Web of Science ®Google Scholar
• Cho SY, Kang CI, Kim J, et al. Can levofloxacin be a useful alternative to trimethoprim–sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother. 2014;58(1):581–583. doi: 10.1128/AAC.01682-13.
   PubMed Web of Science ®Google Scholar
• Bonfiglio G, Cascone C, Azzarelli C, et al. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother. 2000;45(1):115–117. doi: 10.1093/jac/45.1.115.
   PubMed Web of Science ®Google Scholar
• Wang YL, Scipione MR, Dubrovskaya Y, et al. Monotherapy with fluoroquinolone or trimethoprim–sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 2014;58(1):176–182. doi: 10.1128/AAC.01324-13.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother. 2002;49(4):593–596. doi: 10.1093/jac/49.4.593.
   PubMed Web of Science ®Google Scholar
• Tandan M, Cormican M, Vellinga A. Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: a systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents. 2018;52(5):529–540. doi: 10.1016/j.ijantimicag.2018.04.014.
   PubMed Web of Science ®Google Scholar
• Elting LS, Khardori N, Bodey GP, et al. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol. 1990;11(3):134–138. doi: 10.1086/646136.
   PubMed Web of Science ®Google Scholar
• Wei C, Ni W, Cai X, et al. Evaluation of trimethoprim/sulfamethoxazole (SXT), minocycline, tigecycline, moxifloxacin, and ceftazidime alone and in combinations for SXT-susceptible and SXT-resistant Stenotrophomonas maltophilia by in vitro time-kill experiments. PLOS One. 2016;11(3):e0152132. doi: 10.1371/journal.pone.0152132.
   PubMed Web of Science ®Google Scholar
• Paez JG, Costa S. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect. 2008;70(2):101–108. doi: 10.1016/j.jhin.2008.05.020.
   PubMed Web of Science ®Google Scholar
• Apisarnthanarak A, Mayfield JL, Garison T, et al. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Infect Control Hosp Epidemiol. 2003;24(4):269–274. doi: 10.1086/502197.
   PubMed Web of Science ®Google Scholar
• Bao H, Qiao Y, Liu D, et al. The clinical impact of Stenotrophomonas maltophilia bacteremia on the 30-day mortality rate in patients with hematologic disorders: a single-institution experience. Infection. 2020;48(2):205–212. doi: 10.1007/s15010-019-01369-4.
   PubMed Web of Science ®Google Scholar
• Tokatly Latzer I, Nahum E, Cavari Y, et al. Treatment outcomes of Stenotrophomonas maltophilia bacteremia in critically ill children: a multicenter experience. Pediatr Crit Care Med. 2019;20(5):e231–e239. doi: 10.1097/PCC.0000000000001919.
   PubMed Web of Science ®Google Scholar
• Chen Y, Suo J, Du M, et al. Clinical features, outcomes, and risk factors of bloodstream infections due to Stenotrophomonas maltophilia in a tertiary-care hospital of China: a retrospective analysis. Biomed Res Int. 2019;2019:4931501–4931507. doi: 10.1155/2019/4931501.
   PubMed Web of Science ®Google Scholar
• Hotta G, Matsumura Y, Kato K, et al. Risk factors and outcomes of Stenotrophomonas maltophilia bacteremia: a comparison with bacteremia caused by Pseudomonas aeruginosa and Acinetobacter species. PLOS One. 2014;9(11):e112208. doi: 10.1371/journal.pone.0112208.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Kim YC, Ahn JY, et al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains. BMC Infect Dis. 2019;19(1):754. doi: 10.1186/s12879-019-4394-4.
   PubMed Web of Science ®Google Scholar
• Osawa K, Shigemura K, Kitagawa K, et al. Risk factors for death from Stenotrophomonas maltophilia bacteremia. J Infect Chemother. 2018;24(8):632–636. doi: 10.1016/j.jiac.2018.03.011.
   PubMed Web of Science ®Google Scholar
• Kim SH, Cha MK, Kang CI, et al. Pathogenic significance of hemorrhagic pneumonia in hematologic malignancy patients with Stenotrophomonas maltophilia bacteremia: clinical and microbiological analysis. Eur J Clin Microbiol Infect Dis. 2019;38(2):285–295. doi: 10.1007/s10096-018-3425-1.
   PubMed Web of Science ®Google Scholar
• Terlizzi V, Tomaselli M, Giacomini G, et al. Stenotrophomonas maltophilia in people with cystic fibrosis: a systematic review of prevalence, risk factors and management. Eur J Clin Microbiol Infect Dis. 2023;42(11):1285–1296. doi: 10.1007/s10096-023-04648-z.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi: 10.1136/bmj.i4919.
   PubMed Web of Science ®Google Scholar
• Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches the GRADE Working Group. BMC Health Serv Res. 2004;4(1):38. doi: 10.1186/1472-6963-4-38.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926. doi: 10.1136/bmj.39489.470347.AD.
   PubMed Web of Science ®Google Scholar
• Ahlström MG, Knudsen JD, Hertz FB. Stenotrophomonas maltophilia bacteraemia: 61 cases in a tertiary hospital in Denmark. Infect Dis. 2022;54(1):26–35. doi: 10.1080/23744235.2021.
   PubMed Web of Science ®Google Scholar
• Araoka H, Baba M, Yoneyama A. Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996–2009. Eur J Clin Microbiol Infect Dis. 2010;29(5):605–608. doi: 10.1007/s10096-010-0882-6.
   PubMed Web of Science ®Google Scholar
• Aysert-Yildiz P, Yildiz Y, Habibi H, et al. Stenotrophomonas maltophilia bacteremia: from diagnosis to treatment. Infect Dis Clin Microbiol. 2022;4(4):258–267. doi: 10.36519/idcm.2022.187.
   Google Scholar
• Ebara H, Hagiya H, Haruki Y, et al. Clinical characteristics of Stenotrophomonas maltophilia bacteremia: a regional report and a review of a Japanese case series. Intern Med. 2017;56(2):137–142. doi: 10.2169/internalmedicine.56.6141.
   PubMed Web of Science ®Google Scholar
• Fihman V, Le Monnier A, Corvec S, et al. Stenotrophomonas maltophilia – the most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: a prospective multicenter study. J Infect. 2012;64(4):391–398. doi: 10.1016/j.jinf.2012.01.001.
   PubMed Web of Science ®Google Scholar
• Friedman ND, Korman TM, Fairley CK, et al. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect. 2002;45(1):47–53. doi: 10.1053/jinf.2002.0978.
   PubMed Web of Science ®Google Scholar
• Hamdi AM, Fida M, Abu Saleh OM, et al. Stenotrophomonas bacteremia antibiotic susceptibility and prognostic determinants: Mayo Clinic 10-year experience. Open Forum Infect Dis. 2020;7(1):ofaa008. doi: 10.1093/ofid/ofaa008.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Komiya K, Fujita N, et al. Risk factors for 30-day mortality among patients with Stenotrophomonas maltophilia bacteraemia. Infect Dis. 2020;52(6):440–442. doi: 10.1080/23744235.2020.1734653.
   PubMed Web of Science ®Google Scholar
• Jeon YD, Jeong WY, Kim MH, et al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia. Medicine. 2016;95(31):e4375. doi: 10.1097/MD.0000000000004375.
   PubMed Web of Science ®Google Scholar
• Jian J, Xie Z, Chen L. Risk factors for mortality in hospitalized patients with Stenotrophomonas maltophilia bacteremia. Infect Drug Resist. 2022;15:3881–3886. doi: 10.2147/IDR.S371129.
   PubMed Web of Science ®Google Scholar
• Kanchanasuwan S, Rongmuang J, Siripaitoon P, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia. J Clin Med. 2022;11(11):3085. doi: 10.3390/jcm11113085.
   PubMed Web of Science ®Google Scholar
• Metan G, Uzun O. Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2005;49(9):3980–3981. doi: 10.1128/AAC.49.9.3980-3981.2005.
   PubMed Web of Science ®Google Scholar
• Sumida K, Chong Y, Miyake N, et al. Risk factors associated with Stenotrophomonas maltophilia bacteremia: a matched case-control study. PLOS One. 2015;10(7):e0133731. doi: 10.1371/journal.pone.0133731.
   PubMed Web of Science ®Google Scholar
• Watson L, Esterly J, Jensen AO, et al. Sulfamethoxazole/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections. J Glob Antimicrob Resist. 2018;12:104–106. doi: 10.1016/j.jgar.2017.09.015.
   PubMed Web of Science ®Google Scholar
• Lai CH, Chi CY, Chen HP, et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect. 2004;37:350–358.
   PubMedGoogle Scholar
• Muder RR, Harris AP, Muller S, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis. 1996;22(3):508–512. doi: 10.1093/clinids/22.3.508.
   PubMed Web of Science ®Google Scholar
• Muder RR, Yu VL, Dummer JS, et al. Infections caused by Pseudomonas maltophilia. Expanding clinical spectrum. Arch Intern Med. 1987;147(9):1672–1674.
   PubMedGoogle Scholar
• Senol E, DesJardin J, Stark PC, et al. Attributable mortality of Stenotrophomonas maltophilia bacteraemia. Clin Infect Dis. 2002;34(12):1653–1656. doi: 10.1086/340707.
   PubMed Web of Science ®Google Scholar
• Paez JI, Tengan FM, Barone AA, et al. Factors associated with mortality in patients with bloodstream infection and pneumonia due to Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis. 2008;27(10):901–906. doi: 10.1007/s10096-008-0518-2.
   PubMed Web of Science ®Google Scholar
• Garazi M, Singer C, Tai J, et al. Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review. J Hosp Infect. 2012;81(2):114–118. doi: 10.1016/j.jhin.2012.02.008.
   PubMed Web of Science ®Google Scholar
• Del-Toro MD, Rodríguez-Baño J, Martínez-Martínez L, et al. Características epidemiológicas, clínicas y pronósticas de la infecciónpor Stenotrophomonas maltophilia [Epidemiology, clinical features and prognosis of infections due to Stenotrophomonas maltophilia]. Enferm Infecc Microbiol Clin. 2006;24(1):4–9. doi: 10.1157/13083367.
   PubMedGoogle Scholar
• Krcmery V Jr., Pichna P, Oravcova E, et al. Stenotrophomonas maltophilia bacteraemia in cancer patients: report on 31 cases. J Hosp Infect. 1996;34(1):75–77. doi: 10.1016/s0195-6701(96)90129-2.
   PubMed Web of Science ®Google Scholar
• Victor MA, Arpi M, Bruun B, et al. Xanthomonas maltophilia bacteremia in immunocompromised hematological patients. Scand J Infect Dis. 1994;26(2):163–170. doi: 10.3109/00365549409011780.
   PubMed Web of Science ®Google Scholar
• Lai CH, Wong WW, Chin C, et al. Central venous catheter-related Stenotrophomonas maltophilia bacteraemia and associated relapsing bacteraemia in haematology and oncology patients. Clin Microbiol Infect. 2006;12(10):986–991. doi: 10.1111/j.1469-0691.2006.01511.x.
   PubMed Web of Science ®Google Scholar
• Boktour M, Hanna H, Ansari S, et al. Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients. Cancer. 2006;106(9):1967–1973. doi: 10.1002/cncr.21846.
   PubMed Web of Science ®Google Scholar
• Tunger O, Vural S, Cetin CB, et al. Clinical aspects and risk factors of nosocomial Stenotrophomonas maltophilia bacteremia episodes in a Turkish intensive care unit. J Chemother. 2007;19(6):658–664. doi: 10.1179/joc.2007.19.6.658.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious diseases society of America guidance on the treatment of AmpC β-lactamase-producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis. 2022;74(12):2089–2114. doi: 10.1093/cid/ciab1013.
   PubMed Web of Science ®Google Scholar